CTIM-29. PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GBM: IDENTIFICATION OF TREATMENT-INDUCED CD8+CD107A+ CD57+ PD-1- MEMORY T-CELLS THAT ARE ASSOCIATED WITH INCREASED SURVIVAL

Authors: David Peereboom, Ross Lindsay, Michael Badruddoja, L Burt Nabors, Priya Kumthekar, Frank Lieberman, David Tran, Surasak Phuphanich, David Schiff, Jonathan Sherman, Nicholas Butowski, Erin Dunbar, Karen Fink, Fabio Iwamoto, Christopher Moertel, Michael Schulder, Tobias Walbert, Nassir Habboubi, Krzysztof Grzegorzewski, Christopher Brooks, David A Reardon

Published: 2022-11-14

DOI: 10.1093/neuonc/noac209.261

Source: Full article

CTIM-29. PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GBM: IDENTIFICATION OF TREATMENT-INDUCED CD8+CD107A+ CD57+ PD-1- MEMORY T-CELLS THAT ARE ASSOCIATED WITH INCREASED SURVIVAL

Abstract